{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:37:53Z","timestamp":1761511073859,"version":"3.37.3"},"reference-count":165,"publisher":"Bentham Science Publishers Ltd.","issue":"18","funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico","doi-asserted-by":"publisher","award":["448692\/2014-7","449468\/2014-3"],"award-info":[{"award-number":["448692\/2014-7","449468\/2014-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Adrenoceptors are the receptors for catecholamines, adrenaline, and noradrenaline. They are divided in \u03b1 (\u03b11 and \u03b12) and \u03b2 (\u03b21, \u03b22 and \u03b23). \u03b11-adrenoceptors are subdivided in \u03b11A, \u03b11B and \u03b11D. Most tissues express mixtures of \u03b11-adrenoceptors subtypes, which appear to coexist in different densities and ratios, and in most cases, their responses are probably due to the activation of more than one type. The three subtypes of \u03b11-adrenoceptors are G-protein-coupled receptors (GPCR), specifically coupled to Gq\/11. Additionally, the activation of these receptors may activate other signaling pathways or different components of these pathways, which leads to a great variety of possible cellular effects. The first clinically used \u03b11 antagonist was Prazosin for Systemic Arterial Hypertension (SAH). It was followed by its congeners, Terazosin and Doxazosin. Nowadays, there are many classes of \u03b1-adrenergic antagonists with different selectivity profiles. In addition to SAH, the \u03b11-adrenoceptors are used to treat Benign Prostatic Hyperplasia (BPH) and urolithiasis. This antagonism may be part of the mechanism of action of tricyclic antidepressants. Moreover, the activation of these receptors may lead to adverse effects such as orthostatic hypotension, similar to what happens with antidepressants and with some antipsychotics. Structure-activity relationships can explain, in part, how antagonists work and how selective they can be for each one of the subtypes. However, it is necessary to develop new molecules which antagonize the \u03b11- adrenoceptors or make chemical modifications in these molecules to improve the selectivity and pharmacokinetic profile and\/or reduce the adverse effects of known drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557522666220504141949","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T18:43:27Z","timestamp":1651689807000},"page":"2383-2405","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Concise and Useful Guide to Understand How Alpha1 Adrenoceptor Antagonists Work"],"prefix":"10.2174","volume":"22","author":[{"given":"Jana\u00edna V.","family":"dos Anjos","sequence":"first","affiliation":[{"name":"Departamento de Qu\u00edmica Fundamental-Universidade Federal de Pernambuco. Av. Jornalista An\u00edbal Fernandes, s\/n, Cidade Universit\u00e1ria-Recife, PE, 50740-560, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-8033","authenticated-orcid":true,"given":"Alice V.","family":"Ara\u00fajo","sequence":"first","affiliation":[{"name":"N\u00facleo de Sa\u00fade P\u00fablica, Centro Acad\u00eamico de Vit\u00f3ria- Universidade Federal de Pernambuco R. Alto do Reservat\u00f3rio, s\/n Bela Vista-Vit\u00f3ria de Santo Ant\u00e3o, PE, 50608-680, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-2877","authenticated-orcid":true,"given":"Sidiane B.","family":"da Silva","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Nutri\u00e7\u00e3o, Atividade F\u00edsica e Plasticidade Fenot\u00edpica-Centro Acad\u00eamico de Vit\u00f3ria-Universidade Federal de Pernambuco. R. Alto do Reservat\u00f3rio, s\/n Bela Vista-Vit\u00f3ria de Santo Ant\u00e3o, PE, 50608-680, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-1691","authenticated-orcid":true,"given":"Sidney G.D.","family":"Feitosa","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Fundamental-Universidade Federal de Pernambuco. Av. Jornalista An\u00edbal Fernandes, s\/n, Cidade Universit\u00e1ria-Recife, PE, 50740-560, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-2935","authenticated-orcid":true,"given":"Silvia M.","family":"de L. Alves","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Nutri\u00e7\u00e3o, Atividade F\u00edsica e Plasticidade Fenot\u00edpica-Centro Acad\u00eamico de Vit\u00f3ria-Universidade Federal de Pernambuco. R. Alto do Reservat\u00f3rio, s\/n Bela Vista-Vit\u00f3ria de Santo Ant\u00e3o, PE, 50608-680, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth C.A.","family":"Santos","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Nutri\u00e7\u00e3o, Atividade F\u00edsica e Plasticidade Fenot\u00edpica-Centro Acad\u00eamico de Vit\u00f3ria-Universidade Federal de Pernambuco. R. Alto do Reservat\u00f3rio, s\/n Bela Vista-Vit\u00f3ria de Santo Ant\u00e3o, PE, 50608-680, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","volume":"63","author":"Fredriksson R.","year":"2003","unstructured":"Fredriksson R.; Lagerstr\u00f6m M.C.; Lundin L.G.; Schi\u00f6th H.B.; The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003,63(6),1256-1272","journal-title":"Mol Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.phrs.2016.01.031","volume":"112","author":"Pupo A.S.","year":"2016","unstructured":"Pupo A.S.; Duarte D.A.; Lima V.; Teixeira L.B.; Parreiras-E-Silva, L.T.; Costa-Neto, C.M. Recent updates on GPCR biased agonism. Pharmacol Res 2016,112,49-57","journal-title":"Pharmacol Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1152\/ajplegacy.1948.153.3.586","volume":"153","author":"Ahlquist R.P.","year":"1948","unstructured":"Ahlquist R.P.; A study of the adrenotropic receptors. Am J Physiol 1948,153(3),586-600","journal-title":"Am J Physiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/0006-2952(74)90187-7","volume":"23","author":"Langer S.Z.","year":"1974","unstructured":"Langer S.Z.; Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974,23(13),1793-1800","journal-title":"Biochem Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF00501149","volume":"285","author":"Starke K.","year":"1974","unstructured":"Starke K.; Montel H.; Gayk W.; Merker R.; Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery. Alpha-sympathomimetic inhibition of Neurogenic vasoconstriction. Naunyn Schmiedebergs Arch Pharmacol 1974,285(2),133-150","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/214597a0","volume":"214","author":"Lands A.M.","year":"1967","unstructured":"Lands A.M.; Arnold A.; McAuliff J.P.; Luduena F.P.; Brown T.G.; Differentiation of receptor systems activated by sympathomime-tic amines. Nature 1967,214(5088),597-598","journal-title":"Nature"},{"key":"ref=7","first-page":"321","volume":"29","author":"Morrow A.L.","year":"1986","unstructured":"Morrow A.L.; Creese I.; Characterization of alpha 1-adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol Pharmacol 1986,29(4),321-330","journal-title":"Mol Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1749-6632.1995.tb32387.x","volume":"763","author":"Hieble J.P.","year":"1995","unstructured":"Hieble J.P.; Ruffolo R.R.; Jr Possible structural and functional relationships between imidazoline receptors and alpha 2-adrenoceptors. Ann N Y Acad Sci 1995,763(1),8-21","journal-title":"Ann N Y Acad Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/157340910791760082","volume":"6","author":"Du L.","year":"2010","unstructured":"Du L.; Li M.; Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists. Curr Computeraided Drug Des 2010,6(3),165-178","journal-title":"Curr Computeraided Drug Des"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0014-2999(99)00222-8","volume":"375","author":"Zhong H.","year":"1999","unstructured":"Zhong H.; Minneman K.P.; Alpha1-adrenoceptor subtypes. Eur J Pharmacol 1999,375(1-3),261-276","journal-title":"Eur J Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1006\/bbrc.1994.1575","volume":"200","author":"Rokosh D.G.","year":"1994","unstructured":"Rokosh D.G.; Bailey B.A.; Stewart A.F.R.; Karns L.R.; Long C.S.; Simpson P.C.; Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D. Biochem Biophys Res Commun 1994,200(3),1177-1184","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=12","first-page":"1035","volume":"275","author":"Scofield M.A.","year":"1995","unstructured":"Scofield M.A.; Liu F.; Abel P.W.; Jeffries W.B.; Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor sub-types using reverse transcription and a competitive polymerase chain reaction. J Pharmacol Exp Ther 1995,275(2),1035-1042","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ejphar.2019.04.047","volume":"855","author":"Docherty J.R.","year":"2019","unstructured":"Docherty J.R.; The pharmacology of \u03b11-adrenoceptor subtypes. Eur J Pharmacol 2019,855,305-320","journal-title":"Eur J Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1248\/bpb.25.401","volume":"25","author":"Koshimizu T.A.","year":"2002","unstructured":"Koshimizu T.A.; Yamauchi J.; Hirasawa A.; Tanoue A.; Tsujimoto G.; Recent progress in alpha 1-adrenoceptor pharmacology. Biol Pharm Bull 2002,25(4),401-408","journal-title":"Biol Pharm Bull"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"23189","DOI":"10.1074\/jbc.270.39.23189","volume":"270","author":"Hwa J.","year":"1995","unstructured":"Hwa J.; Graham R.M.; Perez D.M.; Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. J Biol Chem 1995,270(39),23189-23195","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0163-7258(00)00092-9","volume":"88","author":"Michelotti G.A.","year":"2000","unstructured":"Michelotti G.A.; Price D.T.; Schwinn D.A.; Alpha 1-adrenergic receptor regulation: Basic science and clinical implications. Pharmacol Ther 2000,88(3),281-309","journal-title":"Pharmacol Ther"},{"key":"ref=17","first-page":"403","volume":"298","author":"Piascik M.T.","year":"2001","unstructured":"Piascik M.T.; Perez D.M.; Alpha1-adrenergic receptors: New insights and directions. J Pharmacol Exp Ther 2001,298(2),403-410","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2210-2-17","volume":"2","author":"Pupo A.S.","year":"2002","unstructured":"Pupo A.S.; Minneman K.P.; Interaction of neuronal nitric oxide synthase with alpha1-adrenergic receptor subtypes in transfected HEK-293 cells. BMC Pharmacol 2002,2(17),17","journal-title":"BMC Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1081\/RRS-120025200","volume":"23","author":"Pupo A.S.","year":"2003","unstructured":"Pupo A.S.; Minneman K.P.; Specific interactions between GC1qR and \u03911\u2010adrenoceptor subtypes. 2003,23(2-3),185-195"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1745-7254.2005.00224.x","volume":"26","author":"Chen Z.J.","year":"2005","unstructured":"Chen Z.J.; Minneman K.P.; Recent progress in alpha1-adrenergic receptor research. Acta Pharmacol Sin 2005,26(11),1281-1287","journal-title":"Acta Pharmacol Sin"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S0021-9258(18)45962-5","volume":"267","author":"Kjelsberg M.A.","year":"1992","unstructured":"Kjelsberg M.A.; Cotecchia S.; Ostrowski J.; Caron M.G.; Lefkowitz R.J.; Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 1992,267(3),1430-1433","journal-title":"J Biol Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1124\/mol.56.5.858","volume":"56","author":"Rossier O.","year":"1999","unstructured":"Rossier O.; Abuin L.; Fanelli F.; Leonardi A.; Cotecchia S.; Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes. Mol Pharmacol 1999,56(5),858-866","journal-title":"Mol Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1476-5381.1996.tb15689.x","volume":"119","author":"Noguera M.A.","year":"1996","unstructured":"Noguera M.A.; Ivorra M.D.; D\u2019Ocon P.; Functional evidence of inverse agonism in vascular smooth muscle. Br J Pharmacol 1996,119(1),158-164","journal-title":"Br J Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.bjp.0704447","volume":"135","author":"Gisbert R.","year":"2002","unstructured":"Gisbert R.; Ziani K.; Miquel R.; Noguera M.A.; Ivorra M.D.; Anselmi E.; D\u2019Ocon P.; Pathological role of a constitutively active popu-lation of alpha(1D)-adrenoceptors in arteries of spontaneously hypertensive rats. Br J Pharmacol 2002,135(1),206-216","journal-title":"Br J Pharmacol"},{"key":"ref=25","first-page":"159","volume":"45","author":"G\u00f3mez-Zamudio J.","year":"2002","unstructured":"G\u00f3mez-Zamudio J.; L\u00e1zaro-Su\u00e1rez M.L.; Villalobos-Molina R.; Urquiza-Mar\u00edn H.; Evidence for the use of agonists to characterize alpha 1-adrenoceptors in isolated arteries of the rat. Proc West Pharmacol Soc 2002,45,159-160","journal-title":"Proc West Pharmacol Soc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1124\/jpet.105.087502","volume":"314","author":"Kamikihara S.Y.","year":"2005","unstructured":"Kamikihara S.Y.; Mueller A.; Lima V.; Silva A.R.T.; da Costa I.B.; Buratini J.; Pupo A.S.; Differential distribution of functional alph1-adrenergic receptor subtypes along the rat tail artery. J Pharmacol Exp Ther 2005,314(2),753-761","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=27","first-page":"1583","volume":"275","author":"Piascik M.T.","year":"1995","unstructured":"Piascik M.T.; Guarino R.D.; Smith M.S.; Soltis E.E.; Saussy D.L.; Perez D.M.; The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther 1995,275(3),1583-1589","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.bbamcr.2011.05.006","volume":"1813","author":"Chotani M.A.","year":"2011","unstructured":"Chotani M.A.; Flavahan N.A.; Intracellular \u03b1(2C)-adrenoceptors: Storage depot, stunted development or signaling domain? Biochim Biophys Acta 2011,1813(8),1495-1503","journal-title":"Biochim Biophys Acta"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/ajpheart.01223.2003","volume":"288","author":"Chotani M.A.","year":"2005","unstructured":"Chotani M.A.; Mitra S.; Eid A.H.; Han S.A.; Flavahan N.A.; Distinct CAMP Signaling pathways differentially regulate A2c-adrenoceptor expression: Role in serum induction in human arteriolar smooth muscle cells. Am J Physiol Heart Circ Physiol 2005,288(1),69-76","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1152\/ajprenal.1993.265.4.F561","volume":"265","author":"Gesek F.A.","year":"1993","unstructured":"Gesek F.A.; Stimulation of alpha 2-adrenergic receptors increases Na(+)-K(+)-ATPase activity in distal convoluted tubule cells. Am J Physiol Renal Physiol 1993,265(4),561-568","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.33549\/physiolres.932189","volume":"60","author":"Pint\u00e9rov\u00e1 M.","year":"2011","unstructured":"Pint\u00e9rov\u00e1 M.; Kune\u0161 J.; Zicha J.; Pint\u00e9rov\u00e1 M.; Altered neural and vascular mechanisms in hypertension. Physiol Res 2011,60(3),381-402","journal-title":"Physiol Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"Giovannitti J.A.","year":"2015","unstructured":"Giovannitti J.A.; Thoms S.M.; Crawford J.J.; Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog 2015,62(1),31-39","journal-title":"Anesth Prog"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000446441","volume":"98","author":"Naguy A.","year":"2016","unstructured":"Naguy A.; Clonidine use in psychiatry: Panacea or panache. Pharmacology 2016,98(1-2),87-92","journal-title":"Pharmacology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0163-7258(01)00156-5","volume":"91","author":"Tam S.W.","year":"2001","unstructured":"Tam S.W.; Worcel M.; Wyllie M.; Yohimbine: A clinical review. Pharmacol Ther 2001,91(3),215-243","journal-title":"Pharmacol Ther"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1152\/ajprenal.2001.281.1.F172","volume":"281","author":"Salomonsson M.","year":"2001","unstructured":"Salomonsson M.; Oker M.; Kim S.; Zhang H.; Faber J.E.; Arendshorst W.J.; A1-adrenoceptor subtypes on rat afferent arterioles as-sessed by radioligand binding and RT-PCR. Am. J. Physiol. -. Ren Physiol 2001,281(1),172-178","journal-title":"Ren Physiol"},{"key":"ref=36","first-page":"441","volume":"298","author":"Faber J.E.","year":"2001","unstructured":"Faber J.E.; Yang N.; Xin X.; Expression of \u03b1-adrenoceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther 2001,298(2),441-452","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"H1923","DOI":"10.1152\/ajpheart.00288.2005","volume":"289","author":"Mart\u00ed D.","year":"2005","unstructured":"Mart\u00ed D.; Miquel R.; Ziani K.; Gisbert R.; Ivorra M. D.; Anselmi E.; Moreno L.; Villagrasa V.; Barettino D.; D\u2019Ocon P.; Correlation between MRNA levels and functional role of \u03911-adrenoceptor subtypes in arteries: Evidence of \u03911L as a functional isoform of the \u03911A-adrenoceptor. Am J Physiol - Hear Circ Physiol 2005,289(558\u20135),H1923-H1932","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0165-1838(96)00114-2","volume":"62","author":"Phillips J.K.","year":"1997","unstructured":"Phillips J.K.; Vidovic M.; Hill C.E.; Variation in mRNA expression of alpha-adrenergic, neurokinin and muscarinic receptors amongst four arteries of the rat. J Auton Nerv Syst 1997,62(1-2),85-93","journal-title":"J Auton Nerv Syst"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.bjp.0700983","volume":"120","author":"Lachnit W.G.","year":"1997","unstructured":"Lachnit W.G.; Tran A.M.; Clarke D.E.; Ford A.P.D.W.; Pharmacological characterization of an alpha 1A-adrenoceptor mediating contrac-tile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol 1997,120(5),819-826","journal-title":"Br J Pharmacol"},{"key":"ref=40","first-page":"854","volume":"283","author":"Piascik M.T.","year":"1997","unstructured":"Piascik M.T.; Hrometz S.L.; Edelmann S.E.; Guarino R.D.; Hadley R.W.; Brown R.D.; Immunocytochemical localization of the alpha-1B adrenergic receptor and the contribution of this and the other subtypes to vascular smooth muscle contraction: Analysis with selective ligands and antisense oligonucleotides. J Pharmacol Exp Ther 1997,283(2),854-868","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1474-8673.2009.00432.x","volume":"29","author":"G\u00f3mez-Zamudio J.H.","year":"2009","unstructured":"G\u00f3mez-Zamudio J.H.; Villalobos-Molina R.; Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol 2009,29(3),117-133","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1476-5381.1995.tb15907.x","volume":"115","author":"Kenny B.A.","year":"1995","unstructured":"Kenny B.A.; Chalmers D.H.; Philpott P.C.; Naylor A.M.; Characterization of an alpha 1D-adrenoceptor mediating the contractile respon-se of rat aorta to noradrenaline. Br J Pharmacol 1995,115(6),981-986","journal-title":"Br J Pharmacol"},{"key":"ref=43","first-page":"134","volume":"272","author":"Schwinn D.A.","year":"1995","unstructured":"Schwinn D.A.; Johnston G.I.; Page S.O.; Mosley M.J.; Wilson K.H.; Worman N.P.; Campbell S.; Fidock M.D.; Furness L.M.; Parry-Smith D.J.; Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: Sequence corrections and direct compa-rison with other species homologues. J Pharmacol Exp Ther 1995,272(1),134-142","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0014-2999(90)90443-A","volume":"186","author":"Piascik M.T.","year":"1990","unstructured":"Piascik M.T.; Kusiak J.W.; Barron K.W.; Alpha 1-adrenoceptor subtypes and the regulation of peripheral hemodynamics in the cons-cious rat. Eur J Pharmacol 1990,186(2-3),273-278","journal-title":"Eur J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1474-8673.2007.00403.x","volume":"27","author":"Mart\u00ednez-Salas S.G.","year":"2007","unstructured":"Mart\u00ednez-Salas S.G.; Campos-Peralta J.M.; Pares-Hipolito J.; Gallardo-Ort\u00edz I.A.; Ibarra M.; Villalobos-Molina R.; Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol 2007,27(3),137-142","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1152\/physiolgenomics.00065.2001","volume":"9","author":"Daly C.J.","year":"2002","unstructured":"Daly C.J.; Deighan C.; McGee A.; Mennie D.; Ali Z.; McBride M.; McGrath J.C.; A knockout approach indicates a minor vasoconstric-tor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 2002,9(2),85-91","journal-title":"Physiol Genomics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.1073\/pnas.132552699","volume":"99","author":"Rokosh D.G.","year":"2002","unstructured":"Rokosh D.G.; Simpson P.C.; Knockout of the alpha 1A\/C-adrenergic receptor subtype: The alpha 1A\/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 2002,99(14),9474-9479","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1474-8673.2011.00468.x","volume":"31","author":"Mart\u00ednez-Salas S.G.","year":"2011","unstructured":"Mart\u00ednez-Salas S.G.; Campos-Peralta J.M.; Pardo J.P.; Hern\u00e1ndez-Mu\u00f1oz R.; Ibarra M.; Tanoue A.; Tsujimoto G.; Villalobos-Molina R.; \u03b1(1D)-Adrenoceptor regulates the vasopressor action of \u03b1(1A)-adrenoceptor in mesenteric vascular bed of \u03b1(1D)-adrenoceptor kno-ckout mice. Auton Autacoid Pharmacol 2011,31(3-4),64-71","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref=49","first-page":"11589","volume":"94","author":"Cavalli A.","year":"1997","unstructured":"Cavalli A.; Lattion A.L.; Hummler E.; Nenniger M.; Pedrazzini T.; Aubert J.F.; Michel M.C.; Yang M.; Lembo G.; Vecchione C.; Mostardini M.; Schmidt A.; Beermann F.; Cotecchia S.; Decreased blood pressure response in mice deficient of the A1b-adrenergic\u2009receptor. Proc. Natl. Acad. Sci. The United States Am 1997,94(21),11589-11594","journal-title":"The United States Am"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1124\/mol.104.007500","volume":"67","author":"Hosoda C.","year":"2005","unstructured":"Hosoda C.; Koshimizu T.A.; Tanoue A.; Nasa Y.; Oikawa R.; Tomabechi T.; Fukuda S.; Shinoura H.; Oshikawa S.; Takeo S.; Kita-mura T.; Cotecchia S.; Tsujimoto G.; Two alpha1-adrenergic receptor subtypes regulating the vasopressor response have differential ro-les in blood pressure regulation. Mol Pharmacol 2005,67(3),912-922","journal-title":"Mol Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000025628","volume":"36","author":"Boer C.","year":"1999","unstructured":"Boer C.; Scheffer G.J.; de Lange J.J.; Westerhof N.; Sipkema P.; Alpha-1-adrenoceptor stimulation induces nitric oxide release in rat pulmonary arteries. J Vasc Res 1999,36(1),79-81","journal-title":"J Vasc Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1152\/jappl.1997.82.6.1918","volume":"82","author":"Zschauer A.O.A.","year":"1997","unstructured":"Zschauer A.O.A.; Sielczak M.W.; Smith D.A.S.; Wanner A.; Norepinephrine-induced contraction of isolated rabbit bronchial artery: Role of alpha 1- and alpha 2-adrenoceptor activation. J Appl Physiol 1997,82(6),1918-1925","journal-title":"J Appl Physiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jphp.12105","volume":"65","author":"Pernomian L.","year":"2013","unstructured":"Pernomian L.; Gomes M.S.; Restini C.B.A.; Pupo A.S.; de Oliveira A.M.; Cross-talk with \u03b22 -adrenoceptors enhances ligand affinity properties from endothelial alpha1 D -adrenoceptors that mediates carotid relaxation. J Pharm Pharmacol 2013,65(9),1337-1346","journal-title":"J Pharm Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1152\/ajpheart.00390.2007","volume":"293","author":"Vinci M.C.","year":"2007","unstructured":"Vinci M.C.; Bellik L.; Filippi S.; Ledda F.; Parenti A.; Trophic effects induced by \u03b1 1D-adrenoceptors on endothelial cells are potentia-ted by hypoxia. Am J Physiol Heart Circ Physiol 2007,293(4),2140-2147","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejphar.2006.06.003","volume":"543","author":"de Andrade C.R.","year":"2006","unstructured":"de Andrade C.R.; Fukada S.Y.; Olivon V.C.; de Godoy M.A.F.; Haddad R.; Eberlin M.N.; Cunha F.Q.; de Souza H.P.; Laurindo F.R.M.; de Oliveira A.M.; Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur J Pharmacol 2006,543(1-3),83-91","journal-title":"Eur J Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejphar.2006.06.070","volume":"546","author":"Mendez E.","year":"2006","unstructured":"Mendez E.; Calzada C.; Ocharan E.; Sierra A.; Castillo C.; Ramirez I.; Meaney E.; Meaney A.; Asbun J.; Miliar A.; Herrera J.; Ceba-llos G.; Differential expression of alpha1-adrenergic receptor subtypes in coronary microvascular endothelial cells in culture. Eur J Pharmacol 2006,546(1-3),127-133","journal-title":"Eur J Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00210-010-0558-x","volume":"382","author":"Jensen B.C.","year":"2010","unstructured":"Jensen B.C.; Swigart P.M.; Montgomery M.D.; Simpson P.C.; Functional alpha-1B adrenergic receptors on human epicardial coronary artery endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2010,382(5-6),475-482","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.lfs.2004.09.008","volume":"76","author":"Sigala S.","year":"2004","unstructured":"Sigala S.; Peroni A.; Mirabella G.; Fornari S.; Palazzolo F.; Pezzotti G.; Simeone C.; Cunico S.C.; Spano P.; Alpha1 adrenoceptor sub-types in human urinary bladder: Sex and regional comparison. Life Sci 2004,76(4),417-427","journal-title":"Life Sci"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0022-5347(01)62836-2","volume":"160","author":"Malloy B.J.","year":"1998","unstructured":"Malloy B.J.; Price D.T.; Price R.R.; Bienstock A.M.; Dole M.K.; Funk B.L.; Rudner X.L.; Richardson C.D.; Donatucci C.F.; Schwinn D.A.; Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998,160(3 Pt 1),937-943","journal-title":"J Urol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/039156030507200104","volume":"72","author":"Peroni A.","year":"2005","unstructured":"Peroni A.; Mirabella G.; Sigala S.; Fornari S.; Palazzolo F.; Faccoli S.; Simeone C.; Pezzotti G.; Spano P.F.; Cunico S.C.; Alpha1 adrenoceptor subtypes in human urinary bladder. Urologia 2005,72(1),10-13","journal-title":"Urologia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/sj.bjp.0703475","volume":"130","author":"Sz\u00e9ll E.A.","year":"2000","unstructured":"Sz\u00e9ll E.A.; Yamamoto T.; de Groat W.C.; Somogyi G.T.; Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 2000,130(7),1685-1691","journal-title":"Br J Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1476-5381.1996.tb15742.x","volume":"119","author":"Nasu K.","year":"1996","unstructured":"Nasu K.; Moriyama N.; Kawabe K.; Tsujimoto G.; Murai M.; Tanaka T.; Yano J.; Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996,119(5),797-803","journal-title":"Br J Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0022-5347(01)65136-X","volume":"157","author":"Walden P.D.","year":"1997","unstructured":"Walden P.D.; Durkin M.M.; Lepor H.; Wetzel J.M.; Gluchowski C.; Gustafson E.L.; Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 1997,157(3),1032-1038","journal-title":"J Urol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0022-5347(01)66704-1","volume":"154","author":"Lepor H.","year":"1995","unstructured":"Lepor H.; Tang R.; Kobayashi S.; Shapiro E.; Forray C.; Wetzel J.M.; Gluchowski C.; Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 1995,154(6),2096-2099","journal-title":"J Urol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0014-2999(93)90527-O","volume":"249","author":"Testa R.","year":"1993","unstructured":"Testa R.; Guarneri L.; Ibba M.; Strada G.; Poggesi E.; Taddei C.; Simonazzi I.; Leonardi A.; Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 1993,249(3),307-315","journal-title":"Eur J Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000030311","volume":"61","author":"Nishi K.","year":"1998","unstructured":"Nishi K.; Wada Y.; Saito M.; Foster H.E.; Weiss R.M.; Latifpour J.; Properties of alpha-1-adrenergic receptors in the rat prostate: Effect of experimental diabetes. Urol Int 1998,61(3),147-153","journal-title":"Urol Int"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1476-5381.1995.tb16356.x","volume":"115","author":"Burt R.P.","year":"1995","unstructured":"Burt R.P.; Chapple C.R.; Marshall I.; Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epi-didymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen. Br J Pharmacol 1995,115(3),467-475","journal-title":"Br J Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/1520-6777(1994)13:3<315::AID-NAU1930130313>3.0.CO;2-G","volume":"13","author":"Morita T.","year":"1994","unstructured":"Morita T.; Ando M.; Kihara K.; Oshima H.; Function and distribution of autonomic receptors in canine ureteral smooth muscle. Neurourol Urodyn 1994,13(3),315-321","journal-title":"Neurourol Urodyn"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1442-2042.2007.01812.x","volume":"14","author":"Itoh Y.","year":"2007","unstructured":"Itoh Y.; Kojima Y.; Yasui T.; Tozawa K.; Sasaki S.; Kohri K.; Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 2007,14(8),749-753","journal-title":"Int J Urol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00345-009-0396-y","volume":"27","author":"Kobayashi S.","year":"2009","unstructured":"Kobayashi S.; Tomiyama Y.; Hoyano Y.; Yamazaki Y.; Kusama H.; Itoh Y.; Kubota Y.; Kohri K.; Gene expressions and mechanical functions of \u03b11-adrenoceptor subtypes in mouse ureter. World J Urol 2009,27(6),775-780","journal-title":"World J Urol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-3-642-16499-6_14","volume":"202","author":"Yamada S.","year":"2011","unstructured":"Yamada S.; Ito Y.; A1-adrenoceptors in the urinary tract. Urin Tract 2011,202,283-306","journal-title":"Urin Tract"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/nau.20642","volume":"28","author":"Barendrecht M.M.","year":"2009","unstructured":"Barendrecht M.M.; Frazier E.P.; Vrydag W.; Alewijnse A.E.; Peters S.L.M.; Michel M.C.; The effect of bladder outlet obstruction on alpha1- and \u03b2-adrenoceptor expression and function. Neurourol Urodyn 2009,28(4),349-355","journal-title":"Neurourol Urodyn"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1442-2042.2012.03223.x","volume":"20","author":"Ishizuka O.","year":"2013","unstructured":"Ishizuka O.; Imamura T.; Kurizaki Y.; Nishizawa O.; Andersson K.E.; Male lower urinary tract symptoms and \u03b11D-adrenoceptors. Int J Urol 2013,20(1),73-78","journal-title":"Int J Urol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/sj.bjp.0701731","volume":"123","author":"Nasu K.","year":"1998","unstructured":"Nasu K.; Moriyama N.; Fukasawa R.; Tsujimoto G.; Tanaka T.; Yano J.; Kawabe K.; Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 1998,123(7),1289-1293","journal-title":"Br J Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0891-0618(97)00042-2","volume":"13","author":"Day H.E.W.","year":"1997","unstructured":"Day H.E.W.; Campeau S.; Watson S.J.; Akil H.; Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 1997,13(2),115-139","journal-title":"J Chem Neuroanat"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cne.20992","volume":"497","author":"Papay R.","year":"2006","unstructured":"Papay R.; Gaivin R.; Jha A.; McCune D.F.; McGrath J.C.; Rodrigo M.C.; Simpson P.C.; Doze V.A.; Perez D.M.; Localization of the mouse alpha1A-adrenergic receptor (AR) in the brain: Alpha1AAR is expressed in neurons, GABAergic interneurons, and NG2 oligoden-drocyte progenitors. J Comp Neurol 2006,497(2),209-222","journal-title":"J Comp Neurol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/bmj.4.5936.108-c","volume":"4","author":"Hayes J.M.","year":"1974","unstructured":"Hayes J.M.; Graham R.M.; O\u2019Connell B.P.; Letter: Prazosin in hypertension. BMJ 1974,4(5936),108-108","journal-title":"BMJ"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/01.RES.48.6.875","volume":"48","author":"De Mey J.","year":"1981","unstructured":"De Mey J.; Vanhoutte P.M.; Uneven distribution of postjunctional alpha 1-and alpha 2-like adrenoceptors in canine arterial and venous smooth muscle. Circ Res 1981,48(6 Pt 1),875-884","journal-title":"Circ Res"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.602","volume":"8","author":"Proudman R.G.W.","year":"2020","unstructured":"Proudman R.G.W.; Pupo A.S.; Baker J.G.; The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors. Pharmacol Res Perspect 2020,8(4)","journal-title":"Pharmacol Res Perspect"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1248\/bpb.35.72","volume":"35","author":"Sato S.","year":"2012","unstructured":"Sato S.; Hatanaka T.; Yuyama H.; Ukai M.; Noguchi Y.; Ohtake A.; Taguchi K.; Sasamata M.; Miyataa K.; Tamsulosin potently and selectively antagonizes human recombinant A1A\/1D-adrenoceptors: Slow dissociation from the A1A-adrenoceptor may account for selec-tivity for A1A-adrenoceptor over A1B-adrenoceptor subtype. Biol Pharm Bull 2012,35(1),72-77","journal-title":"Biol Pharm Bull"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0002-9343(86)90846-6","volume":"80","author":"Kyncl J.J.","year":"1986","unstructured":"Kyncl J.J.; Pharmacology of terazosin. Am J Med 1986,80(5B),12-19","journal-title":"Am J Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0025-7125(16)30778-7","volume":"72","author":"Frishman W.H.","year":"1988","unstructured":"Frishman W.H.; Eisen G.; Lapsker J.; Terazosin: A new long-acting alpha 1-adrenergic antagonist for hypertension. Med Clin North Am 1988,72(2),441-448","journal-title":"Med Clin North Am"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1124\/jpet.119.260216","volume":"371","author":"Quaresma B.M.C.S.","year":"2019","unstructured":"Quaresma B.M.C.S.; Pimenta A.R.; Santos da Silva A.C.; Pupo A.S.; Romeiro L.A.S.; Silva C.L.M.; No\u00ebl F.; Revisiting the pharmaco-dynamic uroselectivity of \u03b11-adrenergic receptor antagonists. J Pharmacol Exp Ther 2019,371(1),106-112","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0014-2999(88)90819-9","volume":"151","author":"Gross G.","year":"1988","unstructured":"Gross G.; Hanft G.; Rugevics C.; 5-Methyl-urapidil discriminates between subtypes of the alpha 1-adrenoceptor. Eur J Pharmacol 1988,151(2),333-335","journal-title":"Eur J Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1476-5381.1989.tb12005.x","volume":"97","author":"Hanft G.","year":"1989","unstructured":"Hanft G.; Gross G.; Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 1989,97(3),691-700","journal-title":"Br J Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/sj.bjp.0702541","volume":"127","author":"Williams T.J.","year":"1999","unstructured":"Williams T.J.; Blue D.R.; Daniels D.V.; Davis B.; Elworthy T.; Gever J.R.; Kava M.S.; Morgans D.; Padilla F.; Tassa S.; Vimont R.L.; Chapple C.R.; Chess-Williams R.; Eglen R.M.; Clarke D.E.; Ford A.P.D.W.; In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. Br J Pharmacol 1999,127(1),252-258","journal-title":"Br J Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0014-2999(95)00471-7","volume":"287","author":"Giardin\u00e0 D.","year":"1995","unstructured":"Giardin\u00e0 D.; Crucianelli M.; Melchiorre C.; Taddei C.; Testa R.; Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist. Eur J Pharmacol 1995,287(1),13-16","journal-title":"Eur J Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/jm980053f","volume":"41","author":"Patane M.A.","year":"1998","unstructured":"Patane M.A.; Scott A.L.; Broten T.P.; Chang R.S.L.; Ransom R.W.; DiSalvo J.; Forray C.; Bock M.G.; 4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6, 7-dimethoxyquinazoline (L-765,314): A potent and se-lective alpha1b adrenergic receptor antagonist. J Med Chem 1998,41(8),1205-1208","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0014-2999(93)90876-J","volume":"238","author":"Sleight A.J.","year":"1993","unstructured":"Sleight A.J.; Koek W.; Bigg D.C.H.; Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: Risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol 1993,238(2-3),407-410","journal-title":"Eur J Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1016\/0014-2999(94)00751-R","volume":"272","author":"Goetz A.S.","year":"1995","unstructured":"Goetz A.S.; King H.K.; Ward S.D.C.; True T.A.; Rimele T.J.; Saussy D.L.; Jr BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. Eur J Pharmacol 1995,272(2-3),R5-R6","journal-title":"Eur J Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1474-8673.2005.00342.x","volume":"25","author":"Cleary L.","year":"2005","unstructured":"Cleary L.; Murad K.; Bexis S.; Docherty J.R.; The alpha (1D)-adrenoceptor antagonist BM7378 is also an alpha (2C)-.Adrenoceptor Antagonist. Auton Autacoid Pharmacol 2005,25(4),135-141","journal-title":"Auton Autacoid Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1476-5381.1996.tb15480.x","volume":"118","author":"Kenny B.A.","year":"1996","unstructured":"Kenny B.A.; Miller A.M.; Williamson I.J.R.; O\u2019Connell J.; Chalmers D.H.; Naylor A.M.; Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: Binding, functional and in vivo studies. Br J Pharmacol 1996,118(4),871-878","journal-title":"Br J Pharmacol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuropharm.2010.03.015","volume":"59","author":"Nojimoto F.D.","year":"2010","unstructured":"Nojimoto F.D.; Mueller A.; Hebeler-Barbosa F.; Akinaga J.; Lima V.; Kiguti L.R.A.; Pupo A.S.; The tricyclic antidepressants amitripty-line, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology 2010,59(1-2),49-57","journal-title":"Neuropharmacology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2008.08.014","volume":"596","author":"Nourian Z.","year":"2008","unstructured":"Nourian Z.; Mulvany M.J.; Nielsen K.B.; Pickering D.S.; Kristensen T.; The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors. Eur J Pharmacol 2008,596(1-3),32-40","journal-title":"Eur J Pharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0163-7258(03)00033-0","volume":"98","author":"Koshimizu T.A.","year":"2003","unstructured":"Koshimizu T.A.; Tanoue A.; Hirasawa A.; Yamauchi J.; Tsujimoto G.; Recent advances in alpha1-adrenoceptor pharmacology. Pharmacol Ther 2003,98(2),235-244","journal-title":"Pharmacol Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0014-2999(83)90199-1","volume":"86","author":"Ruffolo R.R.","year":"1983","unstructured":"Ruffolo R.R.; Rice P.J.; Patil P.N.; Hamada A.; Miller D.D.; Differences in the applicability of the easson-stedman hypothesis to the alpha 1- and alpha 2-adrenergic effects of phenethylamines and imidazolines. Eur J Pharmacol 1983,86(3-4),471-475","journal-title":"Eur J Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"25366","DOI":"10.1074\/jbc.M103152200","volume":"276","author":"Waugh D.J.J.","year":"2001","unstructured":"Waugh D.J.J.; Gaivin R.J.; Zuscik M.J.; Gonzalez-Cabrera P.; Ross S.A.; Yun J.; Perez D.M.; Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. J Biol Chem 2001,276(27),25366-25371","journal-title":"J Biol Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1248\/bpb.30.1891","volume":"30","author":"Takahashi K.","year":"2007","unstructured":"Takahashi K.; Hossain M.; Ahmed M.; Bhuiyan M.A.; Ohnuki T.; Nagatomo T.; Asp125 and Thr130 in transmembrane domain 3 are major sites of alpha1b-adrenergic receptor antagonist binding. Biol Pharm Bull 2007,30(10),1891-1894","journal-title":"Biol Pharm Bull"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1254\/jphs.FP0071412","volume":"106","author":"Nagaoka Y.","year":"2008","unstructured":"Nagaoka Y.; Ahmed M.; Hossain M.; Bhuiyan M.A.; Ishiguro M.; Nakamura T.; Watanabe M.; Nagatomo T.; Amino acids of the hu-man alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci 2008,106(1),114-120","journal-title":"J Pharmacol Sci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bcp.2006.09.010","volume":"73","author":"Perez D.M.","year":"2007","unstructured":"Perez D.M.; Structure-function of alpha1-adrenergic receptors. Biochem Pharmacol 2007,73(8),1051-1062","journal-title":"Biochem Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0968-0896(99)00263-1","volume":"8","author":"Bremner J.B.","year":"2000","unstructured":"Bremner J.B.; Coban B.; Griffith R.; Groenewoud K.M.; Yates B.F.; Ligand design for alpha1 adrenoceptor subtype selective antago-nists. Bioorg Med Chem 2000,8(1),201-214","journal-title":"Bioorg Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1021\/jm00147a042","volume":"28","author":"Giardin\u00e0 D.","year":"1985","unstructured":"Giardin\u00e0 D.; Bertini R.; Brancia E.; Brasili L.; Melchiorre C.; Structure-activity relationships for prazosin and WB 4101 analogues as alpha 1-adrenoreceptor antagonists. J Med Chem 1985,28(9),1354-1357","journal-title":"J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1093-3263(03)00120-7","volume":"21","author":"Balle T.","year":"2003","unstructured":"Balle T.; Andersen K.; S\u00f8by K.K.; Liljefors T.; Alpha(1) adrenoceptor subtype selectivity. 3D-QSAR models for a new class of alpha(1) adrenoceptor antagonists derived from the novel antipsychotic sertindole. J Mol Graph Model 2003,21(6),523-534","journal-title":"J Mol Graph Model"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0014-2999(97)01242-9","volume":"336","author":"Ipsen M.","year":"1997","unstructured":"Ipsen M.; Zhang Y.; Dragsted N.; Han C.; Mulvany M.J.; The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 1997,336(1),29-35","journal-title":"Eur J Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0968-0896(00)00030-4","volume":"8","author":"Pigini M.","year":"2000","unstructured":"Pigini M.; Quaglia W.; Gentili F.; Marucci G.; Cantalamessa F.; Franchini S.; Sorbi C.; Brasili L.; Structure-activity relationship at \u03b1-adrenergic receptors within a series of imidazoline analogues of cirazoline. Bioorg Med Chem 2000,8(5),883-888","journal-title":"Bioorg Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1021\/jm010821u","volume":"44","author":"Barbaro R.","year":"2001","unstructured":"Barbaro R.; Betti L.; Botta M.; Corelli F.; Giannaccini G.; Maccari L.; Manetti F.; Strappaghetti G.; Corsano S.; Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward alpha(1)- and alpha(2)-adrenoceptors. J Med Chem 2001,44(13),2118-2132","journal-title":"J Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1016\/j.bmc.2008.04.058","volume":"16","author":"Handzlik J.","year":"2008","unstructured":"Handzlik J.; Maciag D.; Kubacka M.; Mogilski S.; Filipek B.; Stadnicka K.; Kie\u0107-Kononowicz K.; Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin. Bioorg Med Chem 2008,16(11),5982-5998","journal-title":"Bioorg Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0968-0896(01)00286-3","volume":"10","author":"Barbaro R.","year":"2002","unstructured":"Barbaro R.; Betti L.; Botta M.; Corelli F.; Giannaccini G.; Maccari L.; Manetti F.; Strappaghetti G.; Corsano S.; Synthesis and biologi-cal activity of new 1,4-benzodioxan-arylpiperazine derivatives. Further validation of a pharmacophore model for alpha(1)-adrenoceptor antagonists. Bioorg Med Chem 2002,10(2),361-369","journal-title":"Bioorg Med Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.3390\/molecules26227025","volume":"26","author":"Kucwaj-Brysz K.","year":"2021","unstructured":"Kucwaj-Brysz K.; Dela A.; Podlewska S.; Bednarski M.; Siwek A.; Sata\u0142a G.; Czarnota K.; Handzlik J.; Kie\u0107-Kononowicz K.; The Structural Determinants for \u03b11-Adrenergic\/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives. Molecules 2021,26(22),7025","journal-title":"Molecules"},{"key":"ref=110","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109707","volume":"95","author":"Azevedo H.","year":"2019","unstructured":"Azevedo H.; Ferreira M.; Costa R.W.; Russo V.; Russo E.; Mascarello A.; Guimar\u00e3es C.R.W.; Preclinical characterization of ACH-000029, a novel anxiolytic compound acting on serotonergic and alpha-adrenergic receptors. Prog Neuropsychopharmacol Biol Psychiatry 2019,95","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1016\/j.bmcl.2009.08.068","volume":"19","author":"Wakimoto T.","year":"2009","unstructured":"Wakimoto T.; Nitta M.; Kasahara K.; Chiba T.; Ye Y.; Tsuji K.; Kan T.; Nukaya H.; Ishiguro M.; Koike M.; Yokoo Y.; Suwa Y.; Structure-activity relationship study on alpha1 adrenergic receptor antagonists from beer. Bioorg Med Chem Lett 2009,19(20),5905-5908","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","volume":"47","author":"May L.T.","year":"2007","unstructured":"May L.T.; Leach K.; Sexton P.M.; Christopoulos A.; Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2007,47(1),1-51","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"8299","DOI":"10.1021\/acs.jmedchem.8b00838","volume":"61","author":"Buckley B.J.","year":"2018","unstructured":"Buckley B.J.; Aboelela A.; Minaei E.; Jiang L.X.; Xu Z.; Ali U.; Fildes K.; Cheung C.Y.; Cook S.M.; Johnson D.C.; Bachovchin D.A.; Cook G.M.; Apte M.; Huang M.; Ranson M.; Kelso M.J.; 6-Substituted Hexamethylene Amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer. J Med Chem 2018,61(18),8299-8320","journal-title":"J Med Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/med.21633","volume":"40","author":"Massink A.","year":"2020","unstructured":"Massink A.; Amelia T.; Karamychev A.; IJzerman A.P.; Allosteric modulation of G protein-coupled receptors by amiloride and its deri-vatives. Perspectives for drug discovery? Med Res Rev 2020,40(2),683-708","journal-title":"Med Res Rev"},{"key":"ref=115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174659","volume":"916","author":"Chen J.","year":"2022","unstructured":"Chen J.; Campbell A.P.; Wakelin L.P.G.; Finch A.M.; Characterisation of bis(4-aminoquinoline)s as \u03b11A adrenoceptor allosteric modula-tors. Eur J Pharmacol 2022,916","journal-title":"Eur J Pharmacol"},{"key":"ref=116","first-page":"35","volume":"107","author":"Malachias M.V.B.","year":"2016","unstructured":"Malachias M.V.B.; Paulo C\u00e9sar Veiga Jardim P.C.V.; Almeida F.A.; Lima E.; Feitosa G.S.; 7th Brazilian guideline of arterial hyperten-sion: Chapter 7 - Pharmacological treatment. Arq Bras Cardiol 2016,107(3)(Suppl. 3),35-43","journal-title":"Arq Bras Cardiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"Stanaway J.D.","year":"2018","unstructured":"Stanaway J.D.; Afshin A.; Gakidou E.; Lim S.S.; Abate D.; Abate K.H.; Abbafati C.; Abbasi N.; Abbastabar H.; Abd-Allah F.; Abdela J.; Abdelalim A.; Abdollahpour I.; Abdulkader R.S.; Abebe M.; Abebe Z.; Abera S.F.; Abil O.Z.; Abraha H.N.; Abrham A.R.; Abu-Raddad L.J.; Abu-Rmeileh N.M.E.; Accrombessi M.M.K.; Acharya D.; Acharya P.; Adamu A.A.; Adane A.A.; Adebayo O.M.; Adedoyin R.A.; Adekanmbi V.; Ademi Z.; Adetokunboh O.O.; Adib M.G.; Admasie A.; Adsuar J.C.; Afanvi K.A.; Afarideh M.; Agarwal G.; Aggarwal A.; Aghayan S.A.; Agrawal A.; Agrawal S.; Ahmadi A.; Ahmadi M.; Ahmadieh H.; Ahmed M.B.; Aichour A.N.; Aichour I.; Aichour M.T.E.; Akbari M.E.; Akinyemiju T.; Akseer N.; Al-Aly Z.; Al-Eyadhy A.; Al-Mekhlafi H.M.; Alahdab F.; Alam K.; Alam S.; Alam T.; Alashi A.; Alavian S.M.; Alene K.A.; Ali K.; Ali S.M.; Alijanzadeh M.; Alizadeh-Navaei R.; Aljunid S.M.; Alkerwi A.; Alla F.; Alsharif U.; Altirkawi K.; Alvis-Guzman N.; Amare A.T.; Ammar W.; Anber N.H.; Anderson J.A.; Andrei C.L.; Androudi S.; Animut M.D.; Anjomshoa M.; Ansha M.G.; Ant\u00f3 J.M.; Antonio C.A.T.; Anwari P.; Appiah L.T.; Appiah S.C.Y.; Arabloo J.; Aremu O.; \u00c4rnl\u00f6v J.; Artaman A.; Aryal K.K.; Asayesh H.; Ataro Z.; Ausloos M.; Avokpaho E.F.G.A.; Awasthi A. Ayala; Quintanilla B.P.; Ayer R.; Ayuk T.B.; Azzopardi P.S.; Babazadeh A.; Badali H.; Badawi A.; Balakrishnan K.; Bali A.G.; Ball K.; Ballew S.H.; Banach M.; Banoub J.A.M.; Barac A.; BarkerCollo S.L.; B\u00e4rnighausen T.W.; Barrero L.H.; Basu S.; Baune B.T.; Bazargan-Hejazi S.; Bedi N.; Beghi E.; Behzadifar M.; Behzadifar M.; B\u00e9jot Y.; Bekele B.B.; Bekru E.T.; Belay E.; Belay Y.A.; Bell M.L.; Bello A.K.; Bennett D.A.; Bensenor I.M.; Bergeron G.; Berhane A.; Bernabe E.; Bernstein R.S.; Beuran M.; Beyranvand T.; Bhala N.; Bhalla A.; Bhattarai S.; Bhutta Z.A.; Biadgo B.; Bijani A.; Bikbov B.; Bilano V.; Bililign N.; BinSayeed M.S.; Bisanzio D.; Biswas T.; Bj\u00f8rge T.; Blacker B.F.; Bleyer A.; Borschmann R.; Bou-Orm I.R.; Boufous S.; Bourne R.; Brady O.J.; Brauer M.; Brazinova A.; Breitborde N.J.K.; Brenner H.; Briko A.N.; Britton G.; Brugha T.; Buchbinder R.; Burnett R.T.; Busse R.; Butt Z.A.; Cahill L.E.; CahuanaHurtado L.; Campos-Nonato I.R.; C\u00e1rdenas R.; Carreras G.; Carrero J.J.; Carvalho F.; Casta\u00f1eda-Orjuela C.A.; CastilloRivas J.; Castro F.; Catal\u00e1-L\u00f3pez F.; Causey K.; Cercy K.M.; Cerin E.; Chaiah Y.; Chang H-Y.; Chang J-C.; Chang K-L.; Charlson F.J.; Chattopadhyay A.; Chattu V.K.; Chee M.L.; Cheng C-Y.; Chew A.; Chiang P.P-C.; Chimed-Ochir O.; Chin K.L.; Chitheer A.; Choi J-Y.J.; Chowdhury R.; Christensen H.; Christopher D.J.; Chung S-C.; Cicuttini F.M.; Cirillo M.; Cohen A.J.; ColladoMateo D.; Cooper C.; Cooper O.R.; Coresh J.; Cornaby L.; Cortesi P.A.; Cortinovis M.; Costa M.; Cousin E.; Criqui M.H.; Cromwell E.A.; Cundiff D.K.; Daba A.K.; Dachew B.A.; Dadi A.F.; Damasceno A.A.M.; Dandona L.; Dandona R.; Darby S.C.; Dargan P.I.; Daryani A.; DasGupta R.; DasNeves J.; Dasa T.T.; Dash A.P.; Davitoiu D.V.; Davletov K.; DelaCruzG\u00f3ngora V.; DeLaHoz F.P.; DeLeo D.; DeNeve J-W.; Degenhardt L.; Deiparine S.; Dellavalle R.P.; Demoz G.T.; DenovaGuti\u00e9rrez E.; Deribe K.; Dervenis N.; Deshpande A.; DesJarlais D.C.; Dessie G.A.; Deveber G.A.; Dey S.; Dharmaratne S.D.; Dhimal M.; Dinberu M.T.; Ding E.L.; Diro H.D.; Djalalinia S.; Do H.P.; Dokova K.; Doku D.T.; Doyle K.E.; Driscoll T.R.; Dubey M.; Dubljanin E.; Duken E.E.; Duncan B.B.; Duraes A.R.; Ebert N.; Ebrahimi H.; Ebrahimpour S.; Edvardsson D.; Effiong A.; Eggen A.E.; ElBcheraoui C.; El-Khatib Z.; Elyazar I.R.; Enayati A.; Endries A.Y.; Er B.; Erskine H.E.; Eskandarieh S.; Esteghamati A.; Estep K.; Fakhim H.; Faramarzi M.; Fareed M.; Farid T.A.; Farinha C.S.E.; Farioli A.; Faro A.; Farvid M.S.; Farzaei M.H.; Fatima B.; Fay K.A.; Fazaeli A.A.; Feigin V.L.; Feigl A.B.; Fereshtehnejad S-M.; Fernandes E.; Fernandes J.C.; Ferrara G.; Ferrari A.J.; Ferreira M.L.; Filip I.; Finger J.D.; Fischer F.; Foigt N.A.; Foreman K.J.; Fukumoto T.; Fullman N.; F\u00fcrst T.; Furtado J.M.; Futran N.D.; Gall S.; Gallus S.; Gamkrelidze A.; Ganji M.; Garcia-Basteiro A.L.; Gardner W.M.; Gebre A.K.; Gebremedhin A.T.; Gebremichael T.G.; Gelano T.F.; Geleijnse J.M.; Geramo Y.C.D.; Gething P.W.; Gezae K.E.; Ghadimi R.; Ghadiri K.; GhasemiFalavarjani K.; Ghasemi-Kasman M.; Ghimire M.; Ghosh R.; Ghoshal A.G.; Giampaoli S.; Gill P.S.; Gill T.K.; Gillum R.F.; Ginawi I.A.; Giussani G.; Gnedovskaya E.V.; Godwin W.W.; Goli S.; G\u00f3mez-Dant\u00e9s H.; Gona P.N.; Gopalani S.V.; Goulart A.C.; Grada A.; Grams M.E.; Grosso G.; Gugnani H.C.; Guo Y.; Gupta R.; Gupta R.; Gupta T.; Guti\u00e9rrez R.A.; Guti\u00e9rrez-Torres D.S.; Haagsma J.A.; Habtewold T.D.; Hachinski V.; Hafezi-Nejad N.; Hagos T.B.; Hailegiyorgis T.T.; Hailu G.B.; Haj-Mirzaian A.; Haj-Mirzaian A.; Hamadeh R.R.; Hamidi S.; Handal A.J.; Hankey G.J.; Hao Y.; Harb H.L.; Harikrishnan S.; Haro J.M.; Hassankhani H.; Hassen H.Y.; Havmoeller R.; Hawley C.N.; Hay S.I.; HedayatizadehOmran A.; Heibati B.; Heidari B.; Heidari M.; Hendrie D.; Henok A.; Heredia-Pi I.; Herteliu C.; Heydarpour F.; Heydarpour S.; Hibstu D.T.; Higazi T.B.; Hilawe E.H.; Hoek H.W.; Hoffman H.J.; Hole M.K.; HomaieRad E.; Hoogar P.; Hosgood H.D.; Hosseini S.M.; Hosseinzadeh M.; Hostiuc M.; Hostiuc S.; Hoy D.G.; Hsairi M.; Hsiao T.; Hu G.; Hu H.; Huang J.J.; Hussen M.A.; Huynh C.K.; Iburg K.M.; Ikeda N.; Ilesanmi O.S.; Iqbal U.; Irvani S.S.N.; Irvine C.M.S.; Islam S.M.S.; Islami F.; Jackson M.D.; Jacobsen K.H.; Jahangiry L.; Jahanmehr N.; Jain S.K.; Jakovljevic M.; James S.L.; Jassal S.K.; Jayatilleke A.U.; Jeemon P.; Jha R.P.; Jha V.; Ji J.S.; Jonas J.B.; Jonnagaddala J.; JorjoranShushtari Z.; Joshi A.; Jozwiak J.J.; J\u00fcrisson M.; Kabir Z.; Kahsay A.; Kalani R.; Kanchan T.; Kant S.; Kar C.; Karami M.; KaramiMatin B.; Karch A.; Karema C.; Karimi N.; Karimi S.M.; Kasaeian A.; Kassa D.H.; Kassa G.M.; Kassa T.D.; Kassebaum N.J.; Katikireddi S.V.; Kaul A.; Kawakami N.; Kazemi Z.; Karyani A.K.; Kefale A.T.; Keiyoro P.N.; Kemp G.R.; Kengne A.P.; Keren A.; Kesavachandran C.N.; Khader Y.S.; Khafaei B.; Khafaie M.A.; Khajavi A.; Khalid N.; Khalil I.A.; Khan G.; Khan M.S.; Khan M.A.; Khang Y-H.; Khater M.M.; Khazaei M.; Khazaie H.; Khoja A.T.; Khosravi A.; Khosravi M.H.; Kiadaliri A.A.; Kiirithio D.N.; Kim C-I.; Kim D.; Kim YE.; Kim Y.J.; Kimokoti R.W.; Kinfu Y.; Kisa A.; KissimovaSkarbek K.; Kivim\u00e4ki M.; Knibbs L.D.; Knudsen A.K.S.; Kochhar S.; Kokubo Y.; Kolola T.; Kopec J.A.; Kosen S.; Koul P.A.; Koyanagi A.; Kravchenko M.A.; Krishan K.; Krohn K.J.; Kromhout H.; KuateDefo B.; KucukBicer B.; Kumar G.A.; Kumar M.; Kuzin I.; Kyu H.H.; Lachat C.; Lad D.P.; Lad S.D.; Lafranconi A.; Lalloo R.; Lallukka T.; Lami F.H.; Lang J.J.; Lansingh V.C.; Larson S.L.; Latifi A.; Lazarus J.V.; Lee P.H.; Leigh J.; Leili M.; Leshargie C.T.; Leung J.; Levi M.; Lewycka S.; Li S.; Li Y.; Liang J.; Liang X.; Liao Y.; Liben M.L.; Lim L-L.; Linn S.; Liu S.; Lodha R.; Logroscino G.; Lopez A.D.; Lorkowski S.; Lotufo P.A.; Lozano R.; Lucas T.C.D.; Lunevicius R.; Ma S.; Macarayan E.R.K.; Machado \u00cd.E.; Madotto F.; Mai H.T.; Majdan M.; Majdzadeh R.; Majeed A.; Malekzadeh R.; Malta D.C.; Mamun A.A.; Manda A-L.; Manguerra H.; Mansournia M.A.; Mantovani L.G.; Maravilla J.C.; Marcenes W.; Marks A.; Martin R.V.; Martins S.C.O.; Martins-Melo F.R.; M\u00e4rz W.; Marzan M.B.; Massenburg B.B.; Mathur M.R.; Mathur P.; Matsushita K.; Maulik P.K.; Mazidi M.; McAlinden C.; McGrath J.J.; McKee M.; Mehrotra R.; Mehta K.M.; Mehta V.; Meier T.; Mekonnen F.A.; Melaku Y.A.; Melese A.; Melku M.; Memiah P.T.N.; Memish Z.A.; Mendoza W.; Mengistu D.T.; Mensah G.A.; Mensink G.B.M.; Mereta S.T.; Meretoja A.; Meretoja T.J.; Mestrovic T.; Mezgebe H.B.; Miazgowski B.; Miazgowski T.; Millear A.I.; Miller T.R.; Miller-Petrie M.K.; Mini G.K.; Mirarefin M.; Mirica A.; Mirrakhimov E.M.; Misganaw A.T.; Mitiku H.; Moazen B.; Mohajer B.; Mohammad K.A.; Mohammadi M.; Mohammadifard N.; Mohammadnia-Afrouzi M.; Mohammed S.; Mohebi F.; Mokdad A.H.; Molokhia M.; Momeniha F.; Monasta L.; Moodley Y.; Moradi G.; MoradiLakeh M.; Moradinazar M.; Moraga P.; Morawska L.; MorgadoDa-Costa J.; Morrison S.D.; Moschos M.M.; Mouodi S.; Mousavi S.M.; Mozaffarian D.; Mruts K.B.; Muche A.A.; Muchie K.F.; Mueller U.O.; Muhammed O.S.; Mukhopadhyay S.; Muller K.; Musa K.I.; Mustafa G.; Nabhan A.F.; Naghavi M.; Naheed A.; Nahvijou A.; Naik G.; Naik N.; Najafi F.; Nangia V.; Nansseu J.R.; Nascimento B.R.; Neal B.; Neamati N.; Negoi I.; Negoi R.I.; Neupane S.; Newton C.R.J.; Ngunjiri J.W.; Nguyen A.Q.; Nguyen G.; Nguyen H.T.; Nguyen H.L.T.; Nguyen H.T.; Nguyen M.; Nguyen N.B.; Nichols E.; Nie J.; Ningrum D.N.A.; Nirayo Y.L.; Nishi N.; Nixon M.R.; Nojomi M.; Nomura S.; Norheim O.F.; Noroozi M.; Norrving B.; Noubiap J.J.; Nouri H.R.; NourollahpourShiadeh M.; Nowroozi M.R.; Nsoesie E.O.; Nyasulu P.S.; Obermeyer C.M.; Odell C.M.; Ofori-Asenso R.; Ogbo F.A.; Oh I-H.; Oladimeji O.; Olagunju A.T.; Olagunju T.O.; Olivares P.R.; Olsen H.E.; Olusanya B.O.; Olusanya J.O.; Ong K.L.; Ong S.K.; Oren E.; Orpana H.M.; Ortiz A.; Ota E.; Otstavnov S.S.; \u00d8verland S.; Owolabi M.O.; PA M.; Pacella R.; Pakhare A.P.; Pakpour A.H.; Pana A.; Panda-Jonas S.; Park EK.; Parry C.D.H.; Parsian H.; Patel S.; Pati S.; Patil S.T.; Patle A.; Patton G.C.; Paudel D.; Paulson K.R.; PazBallesteros W.C.; Pearce N.; Pereira A.; Pereira D.M.; Perico N.; Pesudovs K.; Petzold M.; Pham H.Q.; Phillips M.R.; Pillay J.D.; Piradov M.A.; Pirsaheb M.; Pischon T.; Pishgar F.; Plana-Ripoll O.; Plass D.; Polinder S.; Polkinghorne K.R.; Postma M.J.; Poulton R.; Pourshams A.; Poustchi H.; Prabhakaran D.; Prakash S.; Prasad N.; Purcell C.A.; Purwar M.B.; Qorbani M.; Radfar A.; Rafay A.; Rafiei A.; Rahim F.; Rahimi Z.; Rahimi-Movaghar A.; Rahimi-Movaghar V.; Rahman M.; Rahman M.H.; Rahman M.A.; Rai R.K.; Rajati F.; Rajsic S.; Raju S.B.; Ram U.; Ranabhat C.L.; Ranjan P.; Rath G.K.; Rawaf D.L.; Rawaf S.; Reddy K.S.; Rehm C.D.; Rehm J.; Reiner R.C. Jr; Reitsma M.B.; Remuzzi G.; Renzaho A.M.N.; Resnikoff S.; Reynales-Shigematsu L.M.; Rezaei S.; Ribeiro A.L.P.; Rivera J.A.; Roba K.T.; Rodr\u00edguez-Ram\u00edrez S.; Roever L.; Rom\u00e1n Y.; Ronfani L.; Roshandel G.; Rostami A.; Roth G.A.; Rothenbacher D.; Roy A.; Rubagotti E.; Rushton L.; Sabanayagam C.; Sachdev P.S.; Saddik B.; Sadeghi E.; SaeediMoghaddam S.; Safari H.; Safari Y.; SafariFaramani R.; Safdarian M.; Safi S.; Safiri S.; Sagar R.; Sahebkar A.; Sahraian M.A.; Sajadi H.S.; Salam N.; Salamati P.; Saleem Z.; Salimi Y.; Salimzadeh H.; Salomon J.A.; Salvi D.D.; Salz I.; Samy A.M.; Sanabria J.; Sanchez-Ni\u00f1o M.D.; S\u00e1nchezPimienta T.G.; Sanders T.; Sang Y.; Santomauro D.F.; Santos I.S.; Santos J.V.; SantricMilicevic M.M.; SaoJose B.P.; Sardana M.; Sarker A.R.; Sarmiento-Su\u00e1rez R.; Sarrafzadegan N.; Sartorius B.; Sarvi S.; Sathian B.; Satpathy M.; Sawant A.R.; Sawhney M.; Saylan M.; Sayyah M.; Schaeffner E.; Schmidt M.I.; Schneider I.J.C.; Sch\u00f6ttker B.; Schutte A.E.; Schwebel D.C.; Schwendicke F.; Scott J.G.; Seedat S.; Sekerija M.; Sepanlou S.G.; Serre M.L.; Serv\u00e1n-Mori E.; Seyedmousavi S.; Shabaninejad H.; Shaddick G.; Shafieesabet A.; Shahbazi M.; Shaheen A.A.; Shaikh M.A.; ShamahLevy T.; Shams-Beyranvand M.; Shamsi M.; Sharafi H.; Sharafi K.; Sharif M.; Sharif-Alhoseini M.; Sharifi H.; Sharma J.; Sharma M.; Sharma R.; She J.; Sheikh A.; Shi P.; Shibuya K.; Shiferaw M.S.; Shigematsu M.; Shin M-J.; Shiri R.; Shirkoohi R.; Shiue I.; Shokraneh F.; Shoman H.; Shrime M.G.; Shupler M.S.; Si S.; Siabani S.; Sibai A.M.; Siddiqi T.J.; Sigfusdottir I.D.; Sigurvinsdottir R.; Silva D.A.S.; Silva J.P.; Silveira D.G.A.; Singh J.A.; Singh N.P.; Singh V.; Sinha D.N.; Skiadaresi E.; Skirbekk V.; Smith D.L.; Smith M.; Sobaih B.H.; Sobhani S.; Somayaji R.; Soofi M.; Sorensen R.J.D.; Soriano J.B.; Soyiri I.N.; Spinelli A.; Sposato L.A.; Sreeramareddy C.T.; Srinivasan V.; Starodubov V.I.; Steckling N.; Stein D.J.; Stein M.B.; Stevanovic G.; Stockfelt L.; Stokes M.A.; Sturua L.; Subart M.L.; Sudaryanto A.; Sufiyan M.B.; Sulo G.; Sunguya B.F.; Sur P.J.; Sykes B.L.; Szoeke C.E.I.; Tabar\u00e9s-Seisdedos R.; Tabuchi T.; Tadakamadla S.K.; Takahashi K.; Tandon N.; Tassew S.G.; Tavakkoli M.; Taveira N.; Tehrani-Banihashemi A.; Tekalign T.G.; Tekelemedhin S.W.; Tekle M.G.; Temesgen H.; Temsah M-H.; Temsah O.; Terkawi A.S.; Tessema B.; Teweldemedhin M.; Thankappan K.R.; Theis A.; Thirunavukkarasu S.; Thomas H.J.; Thomas M.L.; Thomas N.; Thurston G.D.; Tilahun B.; Tillmann T.; To Q.G.; Tobollik M.; Tonelli M.; Topor-Madry R.; Torre A.E.; Tortajada-Girb\u00e9s M.; Touvier M.; Tovani-Palone M.R.; Towbin J.A.; Tran B.X.; Tran K.B.; Truelsen T.C.; Truong N.T.; Tsadik A.G.; TudorCar L.; Tuzcu E.M.; Tymeson H.D.; Tyrovolas S.; Ukwaja K.N.; Ullah I.; Updike R.L.; Usman M.S.; Uthman O.A.; Vaduganathan M.; Vaezi A.; Valdez P.R.; VanDonkelaar A.; Varavikova E.; Varughese S.; Vasankari T.J.; Venkateswaran V.; Venketasubramanian N.; Villafaina S.; Violante F.S.; Vladimirov S.K.; Vlassov V.; Vollset S.E.; Vos T.; Vosoughi K.; Vu G.T.; Vujcic I.S.; Wagnew F.S.; Waheed Y.; Waller S.G.; Walson J.L.; Wang Y.; Wang Y.; Wang Y-P.; Weiderpass E.; Weintraub R.G.; Weldegebreal F.; Werdecker A.; Werkneh A.A.; West J.J.; Westerman R.; Whiteford H.A.; Widecka J.; Wijeratne T.; Winkler A.S.; Wiyeh A.B.; Wiysonge C.S.; Wolfe C.D.A.; Wong T.Y.; Wu S.; Xavier D.; Xu G.; Yadgir S.; Yadollahpour A.; YahyazadehJabbari S.H.; Yamada T.; Yan L.L.; Yano Y.; Yaseri M.; Yasin Y.J.; Yeshaneh A.; Yimer E.M.; Yip P.; Yisma E.; Yonemoto N.; Yoon S-J.; Yotebieng M.; Younis M.Z.; Yousefifard M.; Yu C.; Zaidi Z.; Zaman S.B.; Zamani M.; ZavalaArciniega L.; Zhang A.L.; Zhang H.; Zhang K.; Zhou M.; Zimsen S.R.M.; Zodpey S.; Murray C.J.L; Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 Lancet 2018,392(10159),1923-1994","journal-title":"Lancet"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"Zhou B.","year":"2017","unstructured":"Zhou B.; Bentham J.; Di Cesare M.; Bixby H.; Danaei G.; Cowan M.J.; Paciorek C.J.; Singh G.; Hajifathalian K.; Bennett J.E.; Taddei C.; Bilano V.; Carrillo-Larco R.M.; Djalalinia S.; Khatibzadeh S.; Lugero C.; Peykari N.; Zhang W.Z.; Lu Y.; Stevens G.A.; Riley L.M.; Bovet P.; Elliott P.; Gu D.; Ikeda N.; Jackson R.T.; Joffres M.; Kengne A.P.; Laatikainen T.; Lam T.H.; Laxmaiah A.; Liu J.; Miranda J.J.; Mondo C.K.; Neuhauser H.K.; Sundstr\u00f6m J.; Smeeth L.; Sori\u0107 M.; Woodward M.; Ezzati M.; Abarca-G\u00f3mez L.; Abdeen Z.A.; Rahim H.A.; AbuRmeileh N.M.; Acosta-Cazares B.; Adams R.; Aekplakorn W.; Afsana K.; Aguilar-Salinas C.A.; Agyemang C.; Ahmadvand A.; Ahrens W.; Al Raddadi R.; Al Woyatan R.; Ali M.M.; Alkerwi A.; Aly E.; Amouyel P.; Amuzu A.; Andersen L.B.; Anderssen S.A.; \u00c4ngquist L.; Anjana R.M.; Ansong D.; Aounallah-Skhiri H.; Ara\u00fajo J.; Ariansen I.; Aris T.; Arlappa N.; Aryal K.; Arveiler D.; Assah F.K.; Assun\u00e7\u00e3o M.C.F.; Avdicov\u00e1 M.; Azevedo A.; Azizi F.; Babu B.V.; Bahijri S.; Balakrishna N.; Bandosz P.; Banegas J.R.; Barbagallo C.M.; Barcel\u00f3 A.; Barkat A.; Barros A.J.D.; Barros M.V.; Bata I.; Batieha A.M.; Baur L.A.; Beaglehole R.; Romdhane H.B.; Benet M.; Benson L.S.; BernabeOrtiz A.; Bernotiene G.; Bettiol H.; Bhagyalaxmi A.; Bharadwaj S.; Bhargava S.K.; Bi Y.; Bikbov M.; Bjerregaard P.; Bjertness E.; Bj\u00f6rkelund C.; Blokstra A.; Bo S.; Bobak M.; Boeing H.; Boggia J.G.; Boissonnet C.P.; Bongard V.; Braeckman L.; Brajkovich I.; Branca F.; Breckenkamp J.; Brenner H.; Brewster L.M.; Bruno G.; Bueno-de-Mesquita H.B.; Bugge A.; Burns C.; Bursztyn M.; de Le\u00f3n A.C.; Cacciottolo J.; Cameron C.; Can G.; C\u00e2ndido A.P.C.; Capuano V.; Cardoso V.C.; Carlsson A.C.; Carvalho M.J.; Casanueva F.F.; Casas J-P.; Caserta C.A.; Chamukuttan S.; Chan A.W.; Chan Q.; Chaturvedi H.K.; Chaturvedi N.; Chen C-J.; Chen F.; Chen H.; Chen S.; Chen Z.; Cheng CY.; Dekkaki I.C.; Chetrit A.; Chiolero A.; Chiou S-T.; ChiritaEmandi A.; Cho B.; Cho Y.; Chudek J.; Cifkova R.; Claessens F.; Clays E.; Concin H.; Cooper C.; Cooper R.; Coppinger T.C.; Costanzo S.; Cottel D.; Cowell C.; Craig C.L.; Crujeiras A.B.; Cruz J.J.; D\u2019Arrigo G.; d\u2019Orsi E.; Dallongeville J.; Damasceno A.; Dankner R.; Dantoft T.M.; Dauchet L.; De Backer G. De; Bacquer D.; de Gaetano G.; De Henauw S.; De Smedt D.; Deepa M.; Dehghan A.; Delisle H.; Deschamps V.; Dhana K. Di; Castelnuovo A.F.; Dias-da-Costa J.S.; Diaz A.; Dickerson T.T.; Do H.T.P.; Dobson A.J.; Donfrancesco C.; Donoso S.P.; D\u00f6ring A.; Doua K.; Drygas W.; Dulskiene V.; D\u017eakula A.; Dzerve V.; Dziankowska-Zaborszczyk E.; Eggertsen R.; Ekelund U.; El Ati J.; Ellert U.; Elliott P.; Elosua R.; Erasmus R.T.; Erem C.; Eriksen L.; de la Pe\u00f1a J.E.; Evans A.; Faeh D.; Fall C.H.; Farzadfar F.; Felix-Redondo F.J.; Ferguson T.S.; Fern\u00e1ndez-Berg\u00e9s D.; Ferrante D.; Ferrari M.; Ferreccio C.; Ferrieres J.; Finn J.D.; Fischer K.; F\u00f6ger B.; Foo L.H.; Forslund A-S.; Forsner M.; Fortmann S.P.; Fouad H.M.; Francis D.K.; Franco M.C.; Franco O.H.; Frontera G.; Fuchs F.D.; Fuchs S.C.; Fujita Y.; Furusawa T.; Gaciong Z.; Gareta D.; Garnett S.P.; Gaspoz J-M.; Gasull M.; Gates L.; Gavrila D.; Geleijnse J.M.; Ghasemian A.; Ghimire A.; Giampaoli S.; Gianfagna F.; Giovannelli J.; Goldsmith R.A.; Gon\u00e7alves H.; Gross M.G.; Rivas J.P.G.; Gottrand F.; Graff-Iversen S.; Grafnetter D.; Grajda A.; Gregor R.D.; Grodzicki T.; Gr\u00f8ntved A.; Gruden G.; Grujic V.; Gu D.; Guan O.P.; Gudnason V.; Guerrero R.; Guessous I.; Guimaraes A.L.; Gulliford M.C.; Gunnlaugsdottir J.; Gunter M.; Gupta P.C.; Gureje O.; Gurzkowska B.; Gutierrez L.; Gutzwiller F.; Hadaegh F.; Halkj\u00e6r J.; Hambleton I.R.; Hardy R.; Harikumar R.; Hata J.; Hayes A.J.; He J.; Hendriks M.E.; Henriques A.; Cadena L.H.; Herrala S.; Heshmat R.; Hihtaniemi I.T.; Ho S.Y.; Ho S.C.; Hobbs M.; Hofman A.; Dinc G.H.; Hormiga C.M.; Horta B.L.; Houti L.; Howitt C.; Htay T.T.; Htet A.S.; Hu Y.; Huerta J.M.; Husseini A.S.; Huybrechts I.; Hwalla N.; Iacoviello L.; Iannone A.G.; Ibrahim M.M.; Ikram M.A.; Irazola V.E.; Islam M.; Ivkovic V.; Iwasaki M.; Jackson R.T.; Jacobs J.M.; Jafar T.; Jamrozik K.; Janszky I.; Jasienska G.; Jelakovic B.; Jiang C.Q.; Joffres M.; Johansson M.; Jonas J.B.; J\u00f8rgensen T.; Joshi P.; Juolevi A.; Jurak G.; Jure\u0161a V.; Kaaks R.; Kafatos A.; KalterLeibovici O.; Kamaruddin N.A.; Kasaeian A.; Katz J.; Kauhanen J.; Kaur P.; Kavousi M.; Kazakbaeva G.; Keil U.; Boker L.K.; Kein\u00e4nen-Kiukaanniemi S.; Kelishadi R.; Kemper H.C.G.; Kengne A.P.; Kersting M.; Key T.; Khader Y.S.; Khalili D.; Khang Y-H.; Khaw K-T.; Kiechl S.; Killewo J.; Kim J.; Klumbiene J.; Kolle E.; Kolsteren P.; Korrovits P.; Koskinen S.; Kouda K.; Koziel S.; Kristensen P.L.; Krokstad S.; Kromhout D.; Kruger H.S.; Kubinova R.; Kuciene R.; Kuh D.; Kujala U.M.; Kula K.; Kulaga Z.; Kumar R.K.; Kurjata P.; Kusuma Y.S.; Kuulasmaa K.; Kyobutungi C.; Laatikainen T.; Lachat C.; Lam T.H.; Landrove O.; Lanska V.; Lappas G.; Larijani B.; Laugsand L.E.; Laxmaiah A.; Bao K.L.N.; Le T.D.; Leclercq C.; Lee J.; Lee J.; Lehtim\u00e4ki T.; Lekhraj R.; Le\u00f3n-Mu\u00f1oz L.M.; Levitt N.S.; Li Y.; Lilly C.L.; Lim W-Y.; Lima-Costa M.F.; Lin H-H.; Lin X.; Linneberg A.; Lissner L.; Litwin M.; Lorbeer R.; Lotufo P.A.; Lozano J.E.; Luksiene D.; Lundqvist A.; Lunet N.; Lytsy P.; Ma G.; Ma J.; Machado-Coelho G.L.L.; Machi S.; Maggi S.; Magliano D.J.; Majer M.; Makdisse M.; Malekzadeh R.; Malhotra R.; Rao K.M.; Malyutina S.; Manios Y.; Mann J.I.; Manzato E.; Margozzini P.; Marques-Vidal P.; Marrugat J.; Martorell R.; Mathiesen E.B.; Matijasevich A.; Matsha T.E.; Mbanya J.C.N.; Posso A.J.M.D.; McFarlane S.R.; McGarvey S.T.; McLachlan S.; McLean R.M.; McNulty B.A.; Khir A.S.M.; Mediene-Benchekor S.; Medzioniene J.; Meirhaeghe A.; Meisinger C.; Menezes A.M.B.; Menon G.R.; Meshram I.I.; Metspalu A.; Mi J.; Mikkel K.; Miller J.C.; Miquel J.F.; Mi\u0161igoj-Durakovic M.; Mohamed M.K.; Mohammad K.; Mohammadifard N.; Mohan V.; Yusoff M.F.M.; M\u00f8ller N.C.; Moln\u00e1r D.; Momenan A.; Mondo C.K.; Monyeki K.D.K.; Moreira L.B.; Morejon A.; Moreno L.A.; Morgan K.; Moschonis G.; Mossakowska M.; Mostafa A.; Mota J.; Motlagh M.E.; Motta J.; Muiesan M.L.; M\u00fcller-Nurasyid M.; Murphy N.; Mursu J.; Musil V.; Nagel G.; Naidu B.M.; Nakamura H.; N\u00e1me\u0161n\u00e1 J.; Nang E.E.K.; Nangia V.B.; Narake S.; Navarrete-Mu\u00f1oz E.M.; Ndiaye N.C.; Neal W.A.; Nenko I.; Nervi F.; Nguyen N.D.; Nguyen Q.N.; NietoMart\u00ednez R.E.; Niiranen T.J.; Ning G.; Ninomiya T.; Nishtar S.; Noale M.; Noboa O.A.; Noorbala A.A.; Noorbala T.; Noto D.; Al Nsour M.; O\u2019Reilly D.; Oh K.; Olinto M.T.A.; Oliveira I.O.; Omar M.A.; Onat A.; Ordunez P.; Osmond C.; Ostojic S.M.; Otero J.A.; Overvad K.; Owusu-Dabo E.; Paccaud F.M.; Padez C.; Pahomova E.; Pajak A.; Palli D.; Palmieri L.; Panda-Jonas S.; Panza F.; Papandreou D.; Parnell W.R.; Parsaeian M.; Pecin I.; Pednekar M.S.; Peer N.; Peeters P.H.; Peixoto S.V.; Pelletier C.; Peltonen M.; Pereira A.C.; P\u00e9rez R.M.; Peters A.; Petkeviciene J.; Pham S.T.; Pigeot I.; Pikhart H.; Pilav A.; Pilotto L.; Pitakaka F.; Plans-Rubi\u00f3 P.; Polakowska M.; Pola\u0161ek O.; Porta M.; Portegies M.L.P.; Pourshams A.; Pradeepa R.; Prashant M.; Price J.F.; Puiu M.; Punab M.; Qasrawi R.F.; Qorbani M.; Radic I.; Radisauskas R.; Rahman M.; Raitakari O.; Raj M.; Rao S.R.; Ramachandran A.; Ramos E.; Rampal S.; Reina D.A.R.; Rasmussen F.; Redon J.; Reganit P.F.M.; Ribeiro R.; Riboli E.; Rigo F.; de Wit T.F.R.; Ritti-Dias R.M.; Robinson S.M.; Robitaille C.; Rodr\u00edguez-Artalejo F.; Rodriguez-Perez del Cristo M.; Rodr\u00edguez-Villamizar L.A.; Rojas-Martinez R.; Rosengren A.; Rubinstein A.; Rui O.; Ruiz-Betancourt B.S.; Horimoto A.R.V.R.; Rutkowski M.; Sabanayagam C.; Sachdev H.S.; Saidi O.; Sakarya S.; Salanave B.; Salazar Martinez E.; Salmer\u00f3n D.; Salomaa V.; Salonen J.T.; Salvetti M.; S\u00e1nchez-Abanto J.; Sans S.; Santos D.; Santos I.S.; dos Santos R.N.; Santos R.; Saramies J.L.; Sardinha L.B.; Margolis G.S.; Sarrafzadegan N.; Saum KU.; Savva S.C.; Scazufca M.; Schargrodsky H.; Schneider I.J.; Schultsz C.; Schutte A.E.; Sen A.; Senbanjo I.O.; Sepanlou S.G.; Sharma S.K.; Shaw J.E.; Shibuya K.; Shin D.W.; Shin Y.; Siantar R.; Sibai A.M.; Silva D.A.S.; Simon M.; Simons J.; Simons L.A.; Sj\u00f6str\u00f6m M.; Skovbjerg S.; Slowikowska-Hilczer J.; Slusarczyk P.; Smeeth L.; Smith M.C.; Snijder M.B.; So H-K.; Sobngwi E.; S\u00f6derberg S.; Solfrizzi V.; Sonestedt E.; Song Y.; S\u00f8rensen T.I.A.; J\u00e9rome C.S.; Soumare A.; Staessen J.A.; Starc G.; Stathopoulou M.G.; Stavreski B.; Steene-Johannessen J.; Stehle P.; Stein A.D.; Stergiou G.S.; Stessman J.; Stieber J.; St\u00f6ckl D.; Stocks T.; Stokwiszewski J.; Stronks K.; Strufaldi M.W.; Sun C-A.; Sundstr\u00f6m J.; Sung Y-T.; Suriyawongpaisal P.; Sy R.G.; Tai E.S.; Tammesoo M-L.; Tamosiunas A.; Tang L.; Tang X.; Tanser F.; Tao Y.; Tarawneh M.R.; Tarqui-Mamani C.B.; Taylor A.; Theobald H.; Thijs L.; Thuesen B.H.; Tjonneland A.; Tolonen H.K.; Tolstrup J.S.; Topbas M.; Top\u00f3r-Madry R.; Tormo M.J.; Torrent M.; Traissac P.; Trichopoulos D.; Trichopoulou A.; Trinh O.T.H.; Trivedi A.; Tshepo L.; TullochReid M.K.; Tuomainen T-P.; Tuomilehto J.; Turley M.L.; Tynelius P.; Tzourio C.; Ueda P.; Ugel E.; Ulmer H.; Uusitalo H.M.T.; Valdivia G.; Valvi D.; van der Schouw Y.T.; Van Herck K.; van Rossem L.; van Valkengoed I.G.M.; Vanderschueren D.; Vanuzzo D.; Vatten L.; Vega T.; Velasquez-Melendez G.; Veronesi G.; Verschuren W.M.M.; Verstraeten R.; Victora C.G.; Viet L.; Viikari-Juntura E.; Vineis P.; Vioque J.; Virtanen J.K.; Visvikis-Siest S.; Viswanathan B.; Vollenweider P.; Voutilainen S.; Vrdoljak A.; Vrijheid M.; Wade A.N.; Wagner A.; Walton J.; Mohamud W.N.W.; Wang M-D.; Wang Q.; Wang Y.X.; Wannamethee S.G.; Wareham N.; Wedderkopp N.; Weerasekera D.; Whincup P.H.; Widhalm K.; Widyahening I.S.; Wiecek A.; Wijga A.H.; Wilks R.J.; Willeit J.; Willeit P.; Williams E.A.; Wilsgaard T.; Wojtyniak B.; Wong T.Y.; Wong-McClure R.A.; Woo J.; Woodward M.; Wu A.G.; Wu F.C.; Wu S.L.; Xu H.; Yan W.; Yang X.; Ye X.; Yiallouros P.K.; Yoshihara A.; Younger-Coleman N.O.; Yusoff A.F.; Yusoff M.F.M.; Zambon S.; Zdrojewski T.; Zeng Y.; Zhao D.; Zhao W.; Zheng Y.; Zhu D.; Zimmermann E.; Zu\u00f1iga Cisneros; J. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 populationbased measurement studies with 19\u00b71 million participants Lancet 2017,389(10064),37-55","journal-title":"Lancet"},{"key":"ref=119","first-page":"75","volume":"13","author":"Ajayi I.O.","year":"2016","unstructured":"Ajayi I.O.; Sowemimo I.O.; Akpa O.M.; Ossai N.E.; Prevalence of hypertension and associated factors among residents of Ibadan-North local government area of Nigeria. Niger J Cardiol 2016,13(1),75","journal-title":"Niger J Cardiol"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198028","volume":"13","author":"Hasan M.","year":"2018","unstructured":"Hasan M.; Sutradhar I.; Akter T.; Das Gupta R.; Joshi H.; Haider M.R.; Sarker M.; Prevalence and determinants of hypertension among adult population in Nepal: Data from Nepal Demographic and Health Survey 2016. PLoS One 2018,13(5)","journal-title":"PLoS One"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.acvdsp.2018.10.215","volume":"11","author":"Oli\u00e9 V.","year":"2019","unstructured":"Oli\u00e9 V.; Perrine A.L.; Lecoffre C.; Blacher J.; National prevalence of hypertension, treatment and control, in France in 2015 and tempo-ral trends since 2006. Arch Cardiovasc Dis Suppl 2019,11(1),96","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048255","volume":"7","author":"Picon R.V.","year":"2012","unstructured":"Picon R.V.; Fuchs F.D.; Moreira L.B.; Riegel G.; Fuchs S.C.; Trends in prevalence of hypertension in Brazil: A systematic review with meta-analysis. PLoS One 2012,7(10)","journal-title":"PLoS One"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"11s","DOI":"10.1590\/s1518-8787.2017051000006","volume":"51","author":"Malta D.C.","year":"2017","unstructured":"Malta D.C.; Bernal R.T.I.; Andrade S.S.C.A.; Silva M.M.A.D.; Velasquez-Melendez G.; Prevalence of and factors associated with self-reported high blood pressure in Brazilian adults. Rev Saude Publica 2017,51(Suppl. 1),11s","journal-title":"Rev Saude Publica"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"469","DOI":"10.5123\/S1679-49742017000300005","volume":"26","author":"Tortorella C.C. da S.","year":"2017","unstructured":"Tortorella C.C. da S.; Corso A.C.T.; Gonz\u00e1les-Chica D.A.; Melhen A.; Time trends of hypertension and diabetes mellitus prevalence among adults registered in the Brazilian National Health System, in Florian\u00f3polis, Santa Catarina State, Brazil, 2004-2011. Epidemiol Serv Saude 2017,26(3),469-480","journal-title":"Epidemiol Serv Saude"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2012.10.025","volume":"698","author":"Kubacka M.","year":"2013","unstructured":"Kubacka M.; Mogilski S.; Filipek B.; Marona H.; The hypotensive activity and alpha1-adrenoceptor antagonistic properties of some aroxyalkyl derivatives of 2-methoxyphenylpiperazine. Eur J Pharmacol 2013,698(1-3),335-344","journal-title":"Eur J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0002-9343(84)90970-7","volume":"76","author":"Zanchetti A.","year":"1984","unstructured":"Zanchetti A.; Summary of prazosin lipid studies. Am J Med 1984,76(2),122-124","journal-title":"Am J Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0002-9343(86)90858-2","volume":"80","author":"Deger G.","year":"1986","unstructured":"Deger G.; Effect of terazosin on serum lipids. Am J Med 1986,80(5B),82-85","journal-title":"Am J Med"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.1996.03530440029033","volume":"275","author":"Grimm R.H.","year":"1996","unstructured":"Grimm R.H.; Flack J.M.; Grandits G.A.; Elmer P.J.; Neaton J.D.; Cutler J.A.; Lewis C.; McDonald R.; Schoenberger J.; Stamler J.; Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996,275(20),1549-1556","journal-title":"JAMA"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40266-018-0580-0","volume":"35","author":"K\u00f6nig M.","year":"2018","unstructured":"K\u00f6nig M.; Gollasch M.; Rosada A.; Demuth I.; Spira D.; Steinhagen-Thiessen E.; Antihypertensive treatment patterns and blood pres-sure control in older adults: Results from the Berlin aging study II. Drugs Aging 2018,35(11),993-1003","journal-title":"Drugs Aging"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1590\/S0066-782X2004001700009","volume":"83","author":"Gus I.","year":"2004","unstructured":"Gus I.; Harzheim E.; Zaslavsky C.; Medina C.; Gus M.; Alegre P.; Prevalence, awareness, and control of systemic arterial hypertension in the state of Rio Grande do Sul. Arq Bras Cardiol 2004,83(5),424-428","journal-title":"Arq Bras Cardiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1751-7176.2010.00392.x","volume":"13","author":"Nelson S.A.E.","year":"2011","unstructured":"Nelson S.A.E.; Dresser G.K.; Vandervoort M.K.; Wong C.J.; Feagan B.G.; Mahon J.L.; Feldman R.D.; Barriers to blood pressure con-trol: A STITCH substudy. J Clin Hypertens (Greenwich) 2011,13(2),73-80","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1590\/S1020-49892010000200003","volume":"27","author":"Nogueira D.","year":"2010","unstructured":"Nogueira D.; Faerstein E.; Coeli C.M.; Chor D.; Lopes C.S.; Werneck G.L.; Awareness, treatment, and control of arterial hypertension: Pr\u00f3-Sa\u00fade study, Brazil. Rev Panam Salud Publica 2010,27(2),103-109","journal-title":"Rev Panam Salud Publica"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4140\/TCP.n.2016.412","volume":"31","author":"Woodard T.J.","year":"2016","unstructured":"Woodard T.J.; Manigault K.R.; McBurrows N.N.; Wray T.L.; Woodard L.M.; Management of benign prostatic hyperplasia in older adults. Consult Pharm 2016,31(8),412-424","journal-title":"Consult Pharm"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"Berry S.J.","year":"1984","unstructured":"Berry S.J.; Coffey D.S.; Walsh P.C.; Ewing L.L.; The development of human benign prostatic hyperplasia with age. J Urol 1984,132(3),474-479","journal-title":"J Urol"},{"key":"ref=135","first-page":"S3","volume":"7","author":"Lepor H.","year":"2005","unstructured":"Lepor H.; Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 2005,7(4)(Suppl. 4),S3-S12","journal-title":"Rev Urol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0022-5347(17)56476-9","volume":"122","author":"Bartsch G.","year":"1979","unstructured":"Bartsch G.; M\u00fcller H.R.; Oberholzer M.; Rohr H.P.; Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979,122(4),487-491","journal-title":"J Urol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0022-5347(17)37546-8","volume":"147","author":"Shapiro E.","year":"1992","unstructured":"Shapiro E.; Becich M.J.; Hartanto V.; Lepor H.; The relative proportion of stromal and epithelial hyperplasia is related to the develop-ment of symptomatic benign prostate hyperplasia. J Urol 1992,147(5),1293-1297","journal-title":"J Urol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0022-5347(17)53216-4","volume":"128","author":"Furuya S.","year":"1982","unstructured":"Furuya S.; Kumamoto Y.; Yokoyama E.; Tsukamoto T.; Izumi T.; Abiko Y.; Alpha-adrenergic activity and urethral pressure in prosta-tic zone in benign prostatic hypertrophy. J Urol 1982,128(4),836-839","journal-title":"J Urol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1464-410X.1975.tb03947.x","volume":"47","author":"Caine M.","year":"1975","unstructured":"Caine M.; Raz S.; Zeigler M.; Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975,47(2),193-202","journal-title":"Br J Urol"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0090-4295(88)90447-5","volume":"32","author":"Lepor H.","year":"1988","unstructured":"Lepor H.; Gup D.I.; Baumann M.; Shapiro E.; Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988,32(6)(Suppl.),21-26","journal-title":"Urology"},{"key":"ref=141","volume":"62","author":"Belayneh M.","year":"2016","unstructured":"Belayneh M.; Korownyk C.; Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with \u03b1-blockers. Can Fam Physician 2016,62(9)","journal-title":"Can Fam Physician"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-015-0549-z","volume":"16","author":"Stearns G.L.","year":"2015","unstructured":"Stearns G.L.; Sandhu J.S.; The impact of medical and surgical treatment for benign prostatic hypertrophy on erectile function. Curr Urol Rep 2015,16(11),1-5","journal-title":"Curr Urol Rep"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1185\/03007995.2013.766594","volume":"29","author":"Yuan J.","year":"2013","unstructured":"Yuan J.; Liu Y.; Yang Z.; Qin X.; Yang K.; Mao C.; The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: An overview of 15 systematic reviews. Curr Med Res Opin 2013,29(3),279-287","journal-title":"Curr Med Res Opin"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1097\/01.ju.0000033280.29453.72","volume":"169","author":"Kyprianou N.","year":"2003","unstructured":"Kyprianou N.; Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance. J Urol 2003,169(4),1520-1525","journal-title":"J Urol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/MOU.0b013e32834d9bfd","volume":"22","author":"Lepor H.","year":"2012","unstructured":"Lepor H.; Kazzazi A.; Djavan B.; \u03b1-Blockers for benign prostatic hyperplasia: The new era. Curr Opin Urol 2012,22(1),7-15","journal-title":"Curr Opin Urol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MOU.0b013e32834d8e87","volume":"22","author":"Juliao A.A.","year":"2012","unstructured":"Juliao A.A.; Plata M.; Kazzazi A.; Bostanci Y.; Djavan B.; American Urological Association and European Association of Urology gui-delines in the management of benign prostatic hypertrophy: Revisited. Curr Opin Urol 2012,22(1),34-39","journal-title":"Curr Opin Urol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/sj.pcan.4500787","volume":"8","author":"Steers W.D.","year":"2005","unstructured":"Steers W.D.; Kirby R.S.; Clinical ease of using doxazosin in BPH patients with and without hypertension. Prostate Cancer Prostatic Dis 2005,8(2),152-157","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=148","first-page":"7","volume":"168","author":"Boyle P.","year":"1995","unstructured":"Boyle P.; Napalkov P.; The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 1995,168,7-12","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1345\/aph.1G586","volume":"40","author":"Beach M.A.","year":"2006","unstructured":"Beach M.A.; Mauro L.S.; Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother 2006,40(7-8),1361-1368","journal-title":"Ann Pharmacother"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(06)69474-9","volume":"368","author":"Hollingsworth J.M.","year":"2006","unstructured":"Hollingsworth J.M.; Rogers M.A.; Kaufman S.R.; Bradford T.J.; Saint S.; Wei J.T.; Hollenbeck B.K.; Medical therapy to facilitate uri-nary stone passage: A meta-analysis. Lancet 2006,368(9542),1171-1179","journal-title":"Lancet"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000019996","volume":"36","author":"H\u00f6fner K.","year":"1999","unstructured":"H\u00f6fner K.; Claes H.; De Reijke T.M.; Folkestad B.; Speakman M.J.; Tamsulosin 0.4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999,36(4),335-341","journal-title":"Eur Urol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2006.06.004","volume":"176","author":"Hellstrom W.J.G.","year":"2006","unstructured":"Hellstrom W.J.G.; Sikka S.C.; Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006,176(4 Pt 1),1529-1533","journal-title":"J Urol"},{"key":"ref=153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174716","volume":"915","author":"Britto-J\u00fanior J.","year":"2022","unstructured":"Britto-J\u00fanior J.; Ribeiro A.; Ximenes L.; Lima A.T.; Jacintho F.F.; Fregonesi A.; M\u00f3nica F.Z.; Antunes E.; De Nucci G.; Alpha1-adrenergic antagonists block 6-nitrodopamine contractions on the rat isolated epididymal vas deferens. Eur J Pharmacol 2022,915","journal-title":"Eur J Pharmacol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0006-3223(99)00234-6","volume":"46","author":"Stone E.A.","year":"1999","unstructured":"Stone E.A.; Quartermain D.; Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol Psychiatry 1999,46(9),1287-1300","journal-title":"Biol Psychiatry"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-2999(81)90319-8","volume":"74","author":"Menkes D.B.","year":"1981","unstructured":"Menkes D.B.; Aghajanian G.K.; alpha 1-Adrenoceptor-mediated responses in the lateral geniculate nucleus are enhanced by chronic anti-depressant treatment. Eur J Pharmacol 1981,74(1),27-35","journal-title":"Eur J Pharmacol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0024-3205(83)90411-3","volume":"33","author":"Menkes D.B.","year":"1983","unstructured":"Menkes D.B.; Kehne J.H.; Gallager D.W.; Aghajanian G.K.; Davis M.; Functional supersensitivity of CNS alpha 1-adrenoceptors follo-wing chronic antidepressant treatment. Life Sci 1983,33(2),181-188","journal-title":"Life Sci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0014-2999(02)01660-6","volume":"444","author":"Nalepa I.","year":"2002","unstructured":"Nalepa I.; Kreiner G.; Kowalska M.; Sanak M.; Zelek-Molik A.; Vetulani J.; Repeated imipramine and electroconvulsive shock increase alpha 1A-adrenoceptor mRNA level in rat prefrontal cortex. Eur J Pharmacol 2002,444(3),151-159","journal-title":"Eur J Pharmacol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1124\/jpet.106.118935","volume":"321","author":"Deupree J.D.","year":"2007","unstructured":"Deupree J.D.; Reed A.L.; Bylund D.B.; Differential effects of the tricyclic antidepressant desipramine on the density of adrenergic recep-tors in juvenile and adult rats. J Pharmacol Exp Ther 2007,321(2),770-776","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/0006-8993(80)91224-X","volume":"194","author":"Rehavi M.","year":"1980","unstructured":"Rehavi M.; Ramot O.; Yavetz B.; Sokolovsky M.; Amitriptyline: Long-term treatment elevates \u03b1-adrenergic and muscarinic receptor binding in mouse brain. Brain Res 1980,194(2),443-453","journal-title":"Brain Res"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.brainres.2009.06.035","volume":"1285","author":"Doze V.A.","year":"2009","unstructured":"Doze V.A.; Handel E.M.; Jensen K.A.; Darsie B.; Luger E.J.; Haselton J.R.; Talbot J.N.; Rorabaugh B.R.; alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res 2009,1285,148-157","journal-title":"Brain Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/ijms23010416","volume":"23","author":"Liu J.","year":"2021","unstructured":"Liu J.; Zhao W.; Li C.; Wu T.; Han L.; Hu Z.; Li X.; Zhou J.; Chen X.; Terazosin stimulates Pgk1 to remedy gastrointestinal disor-ders. Int J Mol Sci 2021,23(1),416","journal-title":"Int J Mol Sci"},{"key":"ref=162","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111617","volume":"201","author":"Serna-Salas S.A.","year":"2022","unstructured":"Serna-Salas S.A.; Arroyave-Ospina J.C.; Zhang M.; Damba T.; Buist-Homan M.; Mu\u00f1oz-Ortega M.H.; Ventura-Ju\u00e1rez J.; Moshage H.; \u03b1-1 Adrenergic receptor antagonist doxazosin reverses hepatic stellate cells activation via induction of senescence. Mech Ageing Dev 2022,201","journal-title":"Mech Ageing Dev"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0006-291X(03)00232-8","volume":"302","author":"Oben J.A.","year":"2003","unstructured":"Oben J.A.; Yang S.; Lin H.; Ono M.; Diehl A.M.; Norepinephrine and neuropeptide Y promote proliferation and collagen gene expres-sion of hepatic myofibroblastic stellate cells. Biochem Biophys Res Commun 2003,302(4),685-690","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1176\/appi.ajp.2020.20050609","volume":"178","author":"Sinha R.","year":"2021","unstructured":"Sinha R.; Wemm S.; Fogelman N.; Milivojevic V.; Morgan P.M.; Angarita G.A.; Hermes G.; Fox H.C.; Moderation of Prazosin\u2019s effi-cacy by alcohol withdrawal symptoms. Am J Psychiatry 2021,178(5),447-458","journal-title":"Am J Psychiatry"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/acer.14378","volume":"44","author":"Milivojevic V.","year":"2020","unstructured":"Milivojevic V.; Angarita G.A.; Hermes G.; Sinha R.; Fox H.C.; Effects of Prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res 2020,44(7),1488-1496","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220504141949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204338\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220504141949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:58:50Z","timestamp":1665680330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204338\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":165,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557522666220504141949","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}